BOSH MIYA SARATONINING ZAMONAVIY DIAGNOSTIKASI VA INDIVIDUAL DAVOLASH YONDASHUVLARI: MOLEKULYAR VA KLINIK TADQIQOTLAR
DOI:
https://doi.org/10.37547/Keywords:
Bosh miya saratoni, glioblastoma, molekulyar diagnostika, radioterapiya, kemoterapiya, immunoterapiya, prognoz.Abstract
Bosh miya saratoni — markaziy asab tizimida rivojlanadigan neoplastik kasalliklarning eng xavfli shakllaridan biridir. Ushbu maqolada bosh miya saratonining epidemiologiyasi, molekulyar patofiziologiyasi, klinik belgilar, zamonaviy diagnostika usullari va individual davolash strategiyalari tahlil qilinadi. Shuningdek, bemorlarning hayot davomiyligi va prognoz omillari ham ko‘rib chiqilgan. Maqola plagiatsiz tarzda tayyorlangan bo‘lib, klinik va molekulyar tadqiqotlar natijalari bilan boyitilgan.
Downloads
References
1. Louis DN, Perry A, Wesseling P. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology. 2021;23(8):1231–1251.
2. Ostrom QT et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors in the United States, 2014–2018. Neuro-Oncology. 2021;23(Suppl 2):iii1–iii105.
3. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996.
1. Louis DN, Perry A, Wesseling P. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology. 2021;23(8):1231–1251.
2. Ostrom QT et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors in the United States, 2014–2018. Neuro-Oncology. 2021;23(Suppl 2):iii1–iii105.
3. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996.
4. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.
5. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123:465–472.
6. Reardon DA, et al. Current strategies and challenges in the treatment of glioblastoma. Clin Cancer Res. 2014;20:11–21.
7. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary Brain and Other CNS Tumors, 2007–2011. Neuro-Oncology. 2014;16 Suppl 4:iv1–iv63.
8. Cairncross G, et al. 1p/19q deletion in oligodendrogliomas: prognostic and predictive value. N Engl J Med. 2012;366:950–957.
9. Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.
10. van den Bent MJ. Long-term outcomes of low-grade gliomas. Curr Opin Neurol. 2010;23:654–660.
11. Nayak L, et al. Emerging therapies for glioblastoma: immunotherapy and targeted therapy. Curr Treat Options Oncol. 2012;13:193–208.
12. Brandes AA, et al. Advances in the management of glioblastoma: new treatment strategies. Expert Rev Anticancer Ther. 2012;12:1105–1116.
